Talnetant, risperidone, or placebo for psychosis in schizophrenia
About this title
Read the official source — NCT00300963This study evaluated the safety and effectiveness of Talnetant for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Talnetant for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 275
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00300963
- Official title
Show the full official title
A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock · Anaheim · Cerritos
17 more locations
- Garden Grove
- Glendale
- National City
- Oceanside
- Pico Rivera
- Rosemead
- San Diego
- Upland
- Washington D.C.
- North Miami
- Atlanta
- St Louis
- Clementon
- Philadelphia
- Austin
- Irving
- Richmond
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Talnetant for people with schizophrenia.
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including Talnetant.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
